Allergy Therapeutics
Update in progressAGY.L (LSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Allergy Therapeutics plc is a commercial biotechnology company focused on diagnosing and treating allergic disorders in Europe and beyond. It markets injectable and sublingual allergen immunotherapies for pollen-related allergies (grasses, weeds, trees) and offers diagnostics products. Its portfolio includes Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus, and it is developing Grass MATA MPL and VLP Peanut. Founded 1998, based in Worthing, UK.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!